Vidac Pharma
10 Hartom Street, 2nd floor
Har Hotzvim
Jerusalem
9777510
Tel: 972-2-595-2090
Fax: 972-2-595-2091
Website: http://www.vidacpharma.com/
Email: info@vidacpharma.com
About Vidac Pharma
Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. We at Vidac are passionate about translating breakthrough science into innovative therapies that address major unmet medical needs.Our breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. This technology holds a promise of delivering first-in-class drugs that are both efficacious and well tolerated.
Vidac was founded by Prof. Max Herzberg, one of the founding fathers of the Israel life sciences industry, and licensed part of its technology from two top Israeli universities, Tel Aviv University and Ben Gurion University.
Vidac's lead drug is currently in clinical development. A Phase 2 clinical study with VDA-1102 ointment in patients suffering from Actinic Keratosis, an early form of skin cancer, will begin in mid-2016.
YEAR FOUNDED:
2011
LEADERSHIP:
CEO: Oren M. Becker
CLINICAL TRIAL:
Please click here for clinical trial information.
4 articles about Vidac Pharma
-
Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate
3/27/2024
Vidac Pharma Holdings Plc. announces it has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use for its VDA-1275 drug candidate, which has shown multiple promising effects in preclinical studies.
-
Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis
7/10/2018
Vidac Pharma announced initiation of a Phase 2b clinical trial of VDA-1102 ointment to treat subjects with actinic keratosis (AK)
-
Vidac Pharma Reports Positive Results From Phase IIa Proof-Of-Concept Trial Of VDA-1102 Ointment In Actinic Keratosis
10/12/2017
-
New Kid Vidac Pharma Completes $9 Million Series A Financing; Advances Phase II VDA-1102
6/29/2016